Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by prophetoffactzon Jan 16, 2023 2:21pm
118 Views
Post# 35226173

RE:RE:RE:Forcing Bioasis to Answer

RE:RE:RE:Forcing Bioasis to Answer

"Cresence was Plan B?!!!???

The Cresence people got 6 million shares or so. Those shares are now worth about $250,000. They aren't Plan B and they never were Plan B. In my opinion, they were likely part of a storyboard developed to promote this sellout."

I said Cresence appears to have been 'Plan A' with the J&J and Neuramedy deals. Marketing BTI as a Phase II clinical stage company they appeared to hope to catalyze new interest in BTI with the Phase II Cresence assets with the J&J and Neuramedy deals on xB3 also. They had hoped for a NASDAQ listing. The called the Cresence deal transformational. That BTI only paid 6 million shares for the Cresence assets can speak to the potential value of xB3 relative to the Cresence assets and could further serve as validation for the xB3 assets. 'Plan A' didn't get the market excited, BTI couldn't launch to NASDAQ, and then BTI missed its debt payments. 'Plan B' appears to be Midatech.

<< Previous
Bullboard Posts
Next >>